Edesa Biotech, Inc. · NASDAQ:EDSA

Edesa Biotech — Investor Presentation (November 2025)

21 slides from Edesa Biotech's investor presentation, Nov 17, 2025

  1. Slide 1: Corporate Presentation

    f 3 \ | Edesa Biotech Corporate Presentation

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "

  3. Slide 3: First-in-Class Development Pipeline

    First-in-Class Development Pipeline Advancing First-in-Class Therapeutics for Immuno-Inflammatory Conditions Franchise Asset Program Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Status Comments CTA granted; Ph2 PoC and drug Anti-CXCL10 EB06 Vitiligo IND in manufacturing plans in (mAb) progress pr

  4. Slide 4: EB06 - Vitiligo

    EB06 - Vitiligo First-in-Class Anti-CXCL10 mAb

  5. Slide 5: A Significant Unaddressed Market

    A Significant Unaddressed Market Latent Market Comprised of Patients Waiting for Better Treatment Options Large Untapped Opportunity Large population but low proportion of patients seeking treatment due to lack of effective and safe treatments Diagnosed with 1.9M New therapies likely to drive market

  6. Slide 6: Vitiligo: A Life-Altering Autoimmune Disease

    Vitiligo IFNγ-CXCL10-CXCR3 Chemokine Axis Play a Key Role in the A Life-Altering Autoimmune Disease Pathogenesis of Vitiligo High Prevalence – 0.5 to 2% Global Population 50% Onset Before Age 20; Must be Managed for Decades Associated with Type 1 Diabetes and Lupus, among others Severe Quality of Li

  7. Slide 7: EB06 – Targeting the Chemokine CXCL10

    EB06 – Targeting the Chemokine CXCL10 Monoclonal Antibody that Directly Binds CXCL10 with High Affinity and Blocks it from Binding to CXCR3 IFNγ CXCL10 EB06 Drug Profile CXCR3A CXCR3B A fully human IgG1k monoclonal antibody Binds specifically to CXCL10 with high Ca2+ flux MAPK Akt PKA affinity Seque

  8. Slide 8: CXCL10 Therapeutic Potential

    CXCL10 Therapeutic Potential Therapeutically Targeting - Substantiated in Preclinical Studies IFNγ CXCL10 1 Melanocyte Apoptosis EB06 CXCL10/CXC3B mediates melanocyte apoptosis and activates anti-melanocytic CD8+ T-cells via CXCR3A 2 Knockout Mice CXCL10 -/- mice do not develop vitiligo CXCR3A CXCR3

  9. Slide 9: Phase 2 Proof of Concept

    Phase 2 Proof of Concept Moderate to Severe Non-Segmental (Generalized) Vitiligo Status CTA approved & IND in progress Subjects Total of 160 evaluable patients randomized 1:1:1 (EB06, 2.5 mg/kg: EB06, 5 mg/kg: EB06, 10mg/kg: Placebo) across up to 25 study centers Treatment Period EB06 or placebo wil

  10. Slide 10: EB06: Anti-CXCL10 Monoclonal Antibody Summary and Next Steps

    EB06: Anti-CXCL10 Monoclonal Antibody Summary and Next Steps Targeted Mechanism of Action 65 Subjects Dosed Biological Activity Phase 2 Ready Manufacturing Binds free and bound CXCL10 No Significant AEs Demonstrated CTA Approved Leading CDMO NEXT STEPS IND in progress CRO identified and ready to be

  11. Slide 11: Daniluromer

    Daniluromer First-in-Class sPLA2 Inhibitor Lead Indication: ACD Status: Topline Results Available

  12. Slide 12: Allergic Contact Dermatitis (ACD)

    Allergic Contact Dermatitis (ACD) The Leading Occupational Health Issue Related to Dermatology ACD Represents a Significant Unmet Need 3,000+ 70% 0 Contact Unable to fully No Known ACD is a Type IV Hypersensitivity Reaction Allergens avoid allergen Labelled Drugs Immune system sensitized following i

  13. Slide 13: Significant Number of Patients with Chronic ACD

    Significant Number of Patients with Chronic ACD $4.7B Total Addressable Market Opportunity 7 major markets (US, UK, Germany, France, Spain, Italy, Japan) and Canada1 “ Physicians strongly desire additional treatment options, especially for hands and face2 “ACD…can make you quit your job.” 30M Patien

  14. Slide 14: Phase 2B Results – Composite CDSI and ISGA Scores

    Phase 2B Results - – Composite CDSI and ISGA Scores 1.0% EB01 Met Primary Endpoint and a Key Secondary Endpoint with Statistical Significance Total CDSI Score* Total ISGA Score* Summary of Results Mean % Improvement from Baseline % Patients with a ≥2 Point Improvement from Baseline P Value = 0.027 P

  15. Slide 15: Paridiprubart

    Paridiprubart First-in-Class Anti-TLR4 mAb

  16. Slide 16: Paridiprubart – Anti-Toll-like Receptor 4 (TLR4) Antibody

    Paridiprubart – Anti-Toll-like Receptor 4 (TLR4) Antibody First-in-Class mAb that Specifically Blocks TLR4 Signalling 1 Paridiprubart interferes with TLR4 dimerization in a ligand independent manner Drug Profile NFκB AP-1 IRF3 A humanized IgG1k monoclonal antibody Binds to TLR4 with high affinity IL

  17. Slide 17: Phase 3 - Baseline Characteristics - ARDS

    Phase 3 - Baseline Characteristics - ARDS Phase 3 ITT Patient Population Encompassed Multiple Potential Etiologies Baseline Conditions Associated with ARDS* Pneumonia Types** 17% Bacterial 2% 29% Fungal 40% Viral Pneumonia 46% 6% Aspiration Unknown **Includes co-infections 20% ARDS Patients Sepsis 1

  18. Slide 18: Baseline Characteristics - ICU

    Baseline Characteristics - ICU Phase 3 Intent-to-Treat (ITT) Patient Population A total of 104 patients hospitalized in the ICU and under invasive mechanical ventilation Patients were required to have a positive Sars Cov2 test 5% (N=5) IMV Only 26% 36% (N=37) Acute Kidney Moderate Severity 38% ARDS

  19. Slide 19: Phase 3 Results – Primary Endpoint 28-Day Mortality

    Phase 3 Results – Primary Endpoint 28-Day Mortality Paridiprubart Met Primary and Secondary Endpoints with Statistical Significance Mortality at Day 28* Mortality at Day 60* Summary of Phase 3 Results n=104 n=104 P Value <0.001 P Value =0.003 28-Day Mortality Rate: Paridiprubart had a relative 52% 5

  20. Slide 20: Paridiprubart Treatment Had Significant Impact on Clinical Improvement

    Paridiprubart Treatment Had Significant Impact on Clinical Improvement Treatment Nearly Doubled the Chance of Recovery by Day 28 - ITT Estimated Proportion Achieving Secondary Endpoint a 2-pt Reduction in WHO Scale (p=0.032) Proportion of Patients Who Achieved at Least a 40% 2-Point Reduction in the

  21. Slide 21: www.EdesaBiotech.com

    www.EdesaBiotech.com [email protected]

Edesa Biotech — Investor Presentation (November 2025) on 6ix